cagrilintide pen Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout Co-formulation of Semaglutide and Cagrilintide

Dosage depends on product form, intended use, clinical context, and individual health factors

Elevated range of motion, lowered pain sensitivity, and improved mobility were indicated

Side-by-side compound comparison Receptor targets Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only Retatrutide GLP-1 + GIP + Glucagon (triple) Half-life Tirzepatide ~5 days Semaglutide ~7 days Retatrutide ~6 days Dosing frequency Tirzepatide Once weekly Semaglutide Once weekly Retatrutide Once weekly Max studied dose Tirzepatide 15 mg / week Semaglutide 2.4 mg / week (Wegovy) Retatrutide 12 mg / week Peak weight loss Tirzepatide 22.5% (SURMOUNT-1, 72 wk) Semaglutide 15.8% (STEP-1, 68 wk) Retatrutide 24.2% (Phase 2, 48 wk) FDA status (June 2026) Tirzepatide Approved (T2D, obesity, OSA) Semaglutide Approved (T2D, obesity, CV risk) Retatrutide Investigational Phase 3 Head-to-head Tirzepatide 20.2% vs semaglutide 13.7% (SURMOUNT-5) Semaglutide Retatrutide Not yet head-to-head vs tirzepatide HFpEF benefit Tirzepatide Yes (SUMMIT, HR 0.62) Semaglutide Yes (STEP-HFpEF) Retatrutide Not yet studied Unique advantage Tirzepatide Best-in-class FDA-approved efficacy

In patients with UC, thiopurines can be initiated if 2 exacerbations have occurred within a 12-month window

Its important to note that while vitamin injections can be beneficial for some people, they are not a good choice for everyone

Among trials with an identified phase, Phase II accounts for the largest share, with 107,793 trials registered globally between 1999 and June 2024, with Statista noting 1,764 in Phase II in 2024 (recorded up to November 2024)